



(51) International Patent Classification:

C07D 417/14 (2006.01) A61P 31/00 (2006.01)
A61K 31/433 (2006.01)

(21) International Application Number:

PCT/IB2016/055795

(22) International Filing Date:

28 September 2016 (28.09.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

3119/DEL/2015 30 September 2015 (30.09.2015) IN

(71) Applicant: DAIICHI SANKYO COMPANY, LIMITED
[JP/JP]; 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP).

(72) Inventors: KHERA, Manoj Kumar; c/o Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon, Haryana 122015 (IN). MATHUR, Tarun; c/o Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon, Haryana 122015 (IN). SATTI-GERI, Jitendra A.; c/o Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon, Haryana 122015 (IN). MAS-UDA, Nobuhisa; c/o Daiichi Sankyo India Pharma Private Limited, Village Sarhaul, Sector-18, Udyog Vihar Industrial Area, Gurgaon, Haryana 122015 (IN). SONEDA, Tsuyoshi; c/o Daiichi Sankyo Company Limited, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP). KAGOSHIMA, Yoshiko; c/o Daiichi Sankyo Company Limited, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP). KONOSU, Toshiyuki; c/o Daiichi Sankyo

Company Limited, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP). SUZUKI, Tetsuya; c/o Daiichi Sankyo Company Limited, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP). YAMAOKA, Makoto; c/o Daiichi Sankyo Company Limited, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP). ITOOKA, Ryo; c/o Daiichi Sankyo Company Limited, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HYDROXYALKYL THIADIAZOLE DERIVATIVES



(I)

(57) Abstract: Problem to be solved. There is a need for a new antibiotic having a novel mechanism of action, which exhibits strong antibacterial activity not only against sensitive bacteria, but also against resistant bacteria thereof, and at the same time possess excellent solubility and safety profile amenable to human use. Solution to the Problem. As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit, possess excellent solubility and safety profile for use in human for the treatment of bacterial infectious diseases.